Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Aug;24(4):715-21.
doi: 10.3346/jkms.2009.24.4.715. Epub 2009 Jul 30.

Clinical characteristics and outcomes of juvenile and adult dermatomyositis

Affiliations
Case Reports

Clinical characteristics and outcomes of juvenile and adult dermatomyositis

Sang-Jun Na et al. J Korean Med Sci. 2009 Aug.

Abstract

Dermatomyositis (DM) is an idiopathic inflammatory myopathy with bimodal onset age distribution. The age of onset is between 5-18 yr in juvenile DM and 45-64 yr in adult DM. DM has a distinct clinical manifestation characterized by proximal muscle weakness, skin rash, extramuscular manifestations (joint contracture, dysphagia, cardiac disturbances, pulmonary symptoms, subcutaneous calcifications), and associated disorders (connective tissue disease, systemic autoimmune diseases, malignancy). The pathogenesis of juvenile and adult DM is presumably similar but there are important differences in some of the clinical manifestations, associated disorders, and outcomes. In this study, we investigated the clinical characteristics and outcomes of 16 patients with juvenile DM and 48 with adult DM. This study recognizes distinctive characteristics of juvenile DM such as higher frequency of neck muscle involvement, subcutaneous calcifications, and better outcomes.

Keywords: Adult Dermatomyositis; Clinical Characteristics; Juvenile Dermatomyositis; Outcomes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Survival curve of 16 patients with juvenile DM and 48 with adult DM. Number of available adult DM patients: 42 at 1-yr follow up, 40 at 3-yr follow up, and 38 at 9-yr follow up.

References

    1. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Skouge JW, Webster SB, Whitaker DC, Butler B, Lowery BJ, Sontheimer RD, Callen JP, Camisa C, Provost TT, Tuffanelli DL. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34:824–829. - PubMed
    1. Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum. 1985;28:249–255. - PubMed
    1. Oddis CV, Conte CG, Steen VD, Medsger TA., Jr Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990;17:1329–1334. - PubMed
    1. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34:732–736. - PubMed
    1. Kaipiainen-Seppanen O, Savolainen A. Incidence of chronic juvenile rheumatic diseases in Finland during 1980-1990. Clin Exp Rheumatol. 1996;14:441–444. - PubMed

Publication types